Form 4: Incyte Executive Matteo Trotta Reports Stock and Option Awards

EVP and GM of Dermatology US, Matteo Trotta, reports acquisition of restricted stock units and stock options in Incyte Corp.

Summary

• Matteo Trotta, EVP and GM of Dermatology US at Incyte Corp, filed a Form 4 detailing changes in beneficial ownership.
• On July 15, 2024, Trotta was awarded 2,646 restricted stock units (RSUs) that vest 25% annually over four years, contingent on continued service.
• These RSUs can be settled for common stock on a one-for-one basis.
• Trotta also acquired 5,921 employee stock options with an exercise price of $64.25.
• These options become exercisable in 37 installments, with 25% vesting after one year and the remainder vesting monthly over three years.
• Following the reported transactions, Trotta beneficially owns 10,474 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested, including the July 15, 2024 grant.
• Trotta also owns 5,921 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to an executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The RSUs vest over four years and the options vest over three years, suggesting a long-term incentive plan for the executive.

Industry Context

Stock option and RSU grants are common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules (25% annually for RSUs and a combination of one-year cliff and monthly vesting for options) are typical vesting arrangements.

Stakeholder Impact

• The equity grants align executive interests with shareholder value.
• Employees may be motivated by the potential for similar compensation structures.

Key Dates